Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in cancer therapy

Suman Bishnoi, Ritudhwaj Tiwari, Sharad Gupta, Siddappa Nagadenahalli Byrareddy, Debasis Nayak

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, systemic treatment-induced toxicity remains a major limiting factor in chemotherapy. To specifically address drug-accessibility and chemotherapy side effects, oncolytic virotherapy (OV) has emerged as a novel cancer treatment alternative. In OV, recombinant viruses with higher replication capacity and stronger lytic properties are being considered for tumor cell-targeting and subsequent cell lysing. Successful application of OVs lies in achieving strict tumor-specific tropism called oncotropism, which is contingent upon the biophysical interactions of tumor cell surface receptors with viral receptors and subsequent replication of oncolytic viruses in cancer cells. In this direction, few viral vector platforms have been developed and some of these have entered pre-clinical/clinical trials. Among these, the Vesicular stomatitis virus (VSV)-based platform shows high promise, as it is not pathogenic to humans. Further, modern molecular biology techniques such as reverse genetics tools have favorably advanced this field by creating efficient recombinant VSVs for OV; some have entered into clinical trials. In this review, we discuss the current status of VSV based oncotherapy, challenges, and future perspectives regarding its therapeutic applications in the cancer treatment.

Original languageEnglish (US)
Article number90
JournalViruses
Volume10
Issue number2
DOIs
StatePublished - Feb 23 2018

Fingerprint

Vesicular Stomatitis
Viruses
Oncolytic Virotherapy
Neoplasms
Therapeutics
Clinical Trials
Oncolytic Viruses
Apoptosis
Reverse Genetics
Drug Therapy
Tropism
Cell Surface Receptors
Molecular Biology

Keywords

  • Apoptosis
  • Oncolytic virus
  • Oncotherapy
  • Tumor lysis
  • Vesicular stomatitis virus (VSV)

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Oncotargeting by Vesicular Stomatitis Virus (VSV) : Advances in cancer therapy. / Bishnoi, Suman; Tiwari, Ritudhwaj; Gupta, Sharad; Byrareddy, Siddappa Nagadenahalli; Nayak, Debasis.

In: Viruses, Vol. 10, No. 2, 90, 23.02.2018.

Research output: Contribution to journalReview article

Bishnoi, Suman ; Tiwari, Ritudhwaj ; Gupta, Sharad ; Byrareddy, Siddappa Nagadenahalli ; Nayak, Debasis. / Oncotargeting by Vesicular Stomatitis Virus (VSV) : Advances in cancer therapy. In: Viruses. 2018 ; Vol. 10, No. 2.
@article{4a367e535653461fa99e714804e21504,
title = "Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in cancer therapy",
abstract = "Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, systemic treatment-induced toxicity remains a major limiting factor in chemotherapy. To specifically address drug-accessibility and chemotherapy side effects, oncolytic virotherapy (OV) has emerged as a novel cancer treatment alternative. In OV, recombinant viruses with higher replication capacity and stronger lytic properties are being considered for tumor cell-targeting and subsequent cell lysing. Successful application of OVs lies in achieving strict tumor-specific tropism called oncotropism, which is contingent upon the biophysical interactions of tumor cell surface receptors with viral receptors and subsequent replication of oncolytic viruses in cancer cells. In this direction, few viral vector platforms have been developed and some of these have entered pre-clinical/clinical trials. Among these, the Vesicular stomatitis virus (VSV)-based platform shows high promise, as it is not pathogenic to humans. Further, modern molecular biology techniques such as reverse genetics tools have favorably advanced this field by creating efficient recombinant VSVs for OV; some have entered into clinical trials. In this review, we discuss the current status of VSV based oncotherapy, challenges, and future perspectives regarding its therapeutic applications in the cancer treatment.",
keywords = "Apoptosis, Oncolytic virus, Oncotherapy, Tumor lysis, Vesicular stomatitis virus (VSV)",
author = "Suman Bishnoi and Ritudhwaj Tiwari and Sharad Gupta and Byrareddy, {Siddappa Nagadenahalli} and Debasis Nayak",
year = "2018",
month = "2",
day = "23",
doi = "10.3390/v10020090",
language = "English (US)",
volume = "10",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Oncotargeting by Vesicular Stomatitis Virus (VSV)

T2 - Advances in cancer therapy

AU - Bishnoi, Suman

AU - Tiwari, Ritudhwaj

AU - Gupta, Sharad

AU - Byrareddy, Siddappa Nagadenahalli

AU - Nayak, Debasis

PY - 2018/2/23

Y1 - 2018/2/23

N2 - Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, systemic treatment-induced toxicity remains a major limiting factor in chemotherapy. To specifically address drug-accessibility and chemotherapy side effects, oncolytic virotherapy (OV) has emerged as a novel cancer treatment alternative. In OV, recombinant viruses with higher replication capacity and stronger lytic properties are being considered for tumor cell-targeting and subsequent cell lysing. Successful application of OVs lies in achieving strict tumor-specific tropism called oncotropism, which is contingent upon the biophysical interactions of tumor cell surface receptors with viral receptors and subsequent replication of oncolytic viruses in cancer cells. In this direction, few viral vector platforms have been developed and some of these have entered pre-clinical/clinical trials. Among these, the Vesicular stomatitis virus (VSV)-based platform shows high promise, as it is not pathogenic to humans. Further, modern molecular biology techniques such as reverse genetics tools have favorably advanced this field by creating efficient recombinant VSVs for OV; some have entered into clinical trials. In this review, we discuss the current status of VSV based oncotherapy, challenges, and future perspectives regarding its therapeutic applications in the cancer treatment.

AB - Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, systemic treatment-induced toxicity remains a major limiting factor in chemotherapy. To specifically address drug-accessibility and chemotherapy side effects, oncolytic virotherapy (OV) has emerged as a novel cancer treatment alternative. In OV, recombinant viruses with higher replication capacity and stronger lytic properties are being considered for tumor cell-targeting and subsequent cell lysing. Successful application of OVs lies in achieving strict tumor-specific tropism called oncotropism, which is contingent upon the biophysical interactions of tumor cell surface receptors with viral receptors and subsequent replication of oncolytic viruses in cancer cells. In this direction, few viral vector platforms have been developed and some of these have entered pre-clinical/clinical trials. Among these, the Vesicular stomatitis virus (VSV)-based platform shows high promise, as it is not pathogenic to humans. Further, modern molecular biology techniques such as reverse genetics tools have favorably advanced this field by creating efficient recombinant VSVs for OV; some have entered into clinical trials. In this review, we discuss the current status of VSV based oncotherapy, challenges, and future perspectives regarding its therapeutic applications in the cancer treatment.

KW - Apoptosis

KW - Oncolytic virus

KW - Oncotherapy

KW - Tumor lysis

KW - Vesicular stomatitis virus (VSV)

UR - http://www.scopus.com/inward/record.url?scp=85042551623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042551623&partnerID=8YFLogxK

U2 - 10.3390/v10020090

DO - 10.3390/v10020090

M3 - Review article

C2 - 29473868

AN - SCOPUS:85042551623

VL - 10

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 2

M1 - 90

ER -